Visualizing & Targeting Cancer

Visualizing & Targeting Cancer

Compassionate. Determined. Infinitely resourceful. Our mission as an oncology company is to develop innovative products that benefit prostate cancer patients and their families. Learn More

Visualizing Prostate Cancer

Visualizing Prostate Cancer

Our development stage imaging agent visualizes prostate cancer, turning watchful waiting into active surveillance. Learn More

Targeting Prostate Cancer

Targeting Prostate Cancer

Our targeted, precise therapeutic candidate selectively attacks prostate cancer cells with minimal damage to surrounding healthy tissue. Our PSMA product candidates include PSMA-ADC in Phase 2 and our small molecule radio therapeutics in pre-clinical development. Learn More

He is our mission

He is your grandfather.father.son.husband.partner.brother.

He is our mission.

Prostate cancer is the second most common form of cancer affecting men in the United States: An estimated one in six will be diagnosed with prostate cancer in his lifetime. The American Cancer Society estimates that approximately 240,000 new cases of prostate cancer will be diagnosed and about 30,000 men will die of the disease this year. Approximately 2 million men in the U.S. currently count themselves among prostate cancer survivors.

Learn More »

About Progenics

Progenics is poised to become a preeminent oncology company focused on developing innovative drugs to improve the lives of prostate cancer patients and their families. Our pipeline includes therapeutic and diagnostic candidates in pre-clinical through late-stage development. Learn more

CEO Video

CEO Video

Watch Progenics’ CEO, Mark Baker, explain our story. Watch Now

Product Pipeline

pipeline-homepage

Our pipeline includes candidates in all stages of development. See All